These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

530 related items for PubMed ID: 34373422

  • 1. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K, Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
    [Abstract] [Full Text] [Related]

  • 2. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
    [Abstract] [Full Text] [Related]

  • 3. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Jan; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report.
    Seo JH, Lim T, Ham A, Kim YA, Lee M.
    Medicine (Baltimore); 2022 Sep 02; 101(35):e30456. PubMed ID: 36107574
    [Abstract] [Full Text] [Related]

  • 10. Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment.
    Hatayama S, Kodama S, Kawana Y, Otake S, Sato D, Horiuchi T, Takahashi K, Kaneko K, Imai J, Katagiri H.
    J Diabetes Investig; 2022 Aug 02; 13(8):1458-1460. PubMed ID: 35396830
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Immune checkpoint inhibitor-related type 1 diabetes mellitus which develops long after treatment discontinuation: a case report and review of literature.
    Obata Y, Takemoto M, Sakaue TA, Kawata S, Mukai K, Miyashita K, Kozawa J, Nishizawa H, Shimomura I.
    Diabetol Int; 2024 Jul 02; 15(3):605-610. PubMed ID: 39101180
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a case report.
    Kikuchi F, Saheki T, Imachi H, Kobayashi T, Fukunaga K, Ibata T, Sato S, Ban N, Lyu J, Japar S, Murao K.
    J Med Case Rep; 2021 Apr 23; 15(1):214. PubMed ID: 33892782
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.